The Rodent Electronic Nicotine Delivery System: Description and Validation

of an Apparatus for Nose-Only E-Cigarette Aerosol Inhalation in Freely Moving Rats

Amy L. Odum[1], Mariah E. Willis-Moore[1], Kiernan T. Callister[1], Jeremy M. Haynes[2],

Charles C. J. Frye[3], Lucy N. Scribner[1], David N. Legaspi[1], Daniel Santos Da Silva[1], Aaron L.

Olsen[1], Tadd T. Truscott[4], Preston T. Alden[1], Rick A. Bevins[5], Adam M. Leventhal[6],

Stephen T. Lee[7], and Brenna Gomer[8]

Affiliations

Utah State University[1], Temple University[2], Cameron University[3], King Abdullah University of

Science and Technology[4], University of Nebraska-Lincoln[5], University of Southern California[6],

Poisonous Plant Research Laboratory, Agricultural Research Service, United States Department

of Agriculture, Logan UT[7], University of Utah[8]

Author Note

Authors Odum, Willis-Moore, Callister, Alden, Scribner, Da Silva, and Legaspi were supported

in part during the preparation of this manuscript by R21 DA053818 Cutting Edge Basic Research

(CEBRA) Award from the National Institute on Drug Abuse. In addition, Da Silva was supported

in part by a Research Catalyst Award from the Alzheimer's Disease and Dementia Research

Center of Utah State University, and Odum and Willis-Moore were supported during portions of

this project by a SPARC (Seed Program to Advance Research Collaborations) grant from USU.

Acknowledgements: The authors express their gratitude to the many individuals who

contributed to this project. The authors acknowledge prior graduate students Ryan Becker,

Devanio Cousins, Annie Galizio, D. Perez, and Caroline Towse for their collaboration and

support on earlier versions of this project. We thank Spencer Mathias for his help designing the

original nose port. We also thank Megan Raddatz for helping with the blood sampling process.
The authors thank Josephine Hannah for assistance in withdrawal video coding, as well as
Avonlea Richards and Dillon Marstella as exceptional paid research assistants and supervisors.
The authors recognize the dedicated research assistants Erin McQuillen, Kelsey Summarell,
Bailey Herbert, Brooke Piippo, and Jesslyn Hoffman, whose commitment and hard work were
invaluable. Additionally, the authors appreciate the contributions of research assistants who
worked with us for one semester: Kaylana Brown, Callissa Candalot, Katherine Flores-Cabrera,
Elisabeth Himelberger, Lexie Myers, Brandi Smith, and Ryan Thrasher. Finally, we would like to
acknowledge our research subjects for their contributions to our science.

Funding Statement: This research was supported by a Cutting-Edge Basic Research Award
(CEBRA) from the National Institute on Drug Abuse (RD21 DA053818) and by a SPARC (Seed
Program to Advance Research Collaborations) grant from USU.

Abstract

Tobacco use is the leading cause of death globally and in the U.S. After decades of decline,

driven by decreases in combusted tobacco use, nicotine product use has increased due to

Electronic Nicotine Delivery Systems (ENDS), also known as e-cigarettes or vapes. Preclinical

models of nicotine self-administration can serve as important lodestars in the search for effective

intervention and prevention tactics. Current variants of the task have substantial limitations,

however. Therefore, we created the Rodent Electronic Nicotine Delivery System (RENDS), a

novel low-cost non-proprietary snout-only preclinical model of self-administration of nicotine

aerosol. We validated the RENDS using two techniques. First, we confirmed that RENDS

sequesters nicotine aerosol in the nose port by measuring fine particulate matter (PM < 2.5

microns) generated by e-cigarettes. The PM2.5 levels in the chamber were similar to room air

when the vacuum system was in operation. We also demonstrated that rats robustly

self-administer flavored nicotine aerosol, resulting in high blood levels of cotinine (the major

nicotine metabolite) and spontaneous somatic withdrawal symptoms. Thus, we provide strong

validation of the operation and function of the RENDS, opening the door to an open-source

preclinical aerosol model of nicotine self-administration that is relatively low cost. Four existing

operant chambers can be retrofitted with the RENDS for less than $1,300 (under $325/chamber).

All RENDS diagrams and plans for custom designed components can be found freely on our

open science framework site (OSF;

https://osf.io/x2pqf/?view_only=775b55435b8e428f98e6da384ef7889d).

Keywords: self-administration, nicotine aerosol, preclinical, snout-only, vaping, rats

The Rodent Electronic Nicotine Delivery System: Description and Validation

of an Apparatus for Nose-Only E-Cigarette Aerosol Inhalation in Freely Moving Rats

Tobacco use is the leading cause of death globally as well as in the U.S., causing nearly 8 million deaths per year (Reitsma et al., 2021). Nicotine is the primary compound responsible for the extensive use of tobacco (Bevins et al., 2018; Le Foll et al., 2022; United States Department of Health and Human Services [USDHHS], 2014). After decades of decline, nicotine use has increased due to Electronic Nicotine Delivery Systems (ENDS; Cornelius et al., 2022; Cullen et al., 2018). Electronic Nicotine Delivery Systems, also called e-cigarettes or vapes, come in a variety of shapes and sizes, but in general these devices create an aerosol by heating a liquid containing nicotine, most often with flavoring. At the peak, nearly 30% of high school students and over 10% of middle school students in the U.S. used ENDS (Cullen et al., 2019). Current use remains alarmingly high in youth and young adults (Birdsey et al., 2023; Kelsh et al., 2023; Park-Lee et al., 2021), exposing millions of young people to nicotine. Vaping nicotine increases the likelihood of subsequent combusted tobacco use (Center for Disease and Prevention Control [CDC], 2024; Hair et al., 2021; Tashakkori et al., 2023), vulnerability to drug use and misuse (USDHHS, 2016), and harms brain development in adolescents (Castro et al., 2023; England et al., 2015; Leslie, 2020; Yuan et al., 2015). Furthermore, both the constituents of the aerosol as well as nicotine can injure the cardiovascular and respiratory systems (Alanazi et al., 2020; Morris et al., 2021; Park et al., 2019; Qazi et al., 2024; USDHHS, 2016).

To investigate ENDS use, a preclinical model is needed. Human studies are important but lack control and the ability to isolate key factors contributing to use and misuse (Herman & Tarran, 2020; Jackson et al., 2020). Most prior research on nicotine use in rodents has employed intravenous (IV) self-administration, which allows for strong experimental control, but requires

surgery and is limited by relatively short catheter patency duration and the difficulty of

implementation with smaller animals (Pogun et al., 2017). Current research into ENDS use in

rodents has employed the whole-body exposure technique in an air-tight "vapor chamber." In

some models, exposure is involuntary (e.g., Frie et al., 2023), whereas in others, rodents can

make a response (e.g., a lever press) to introduce aerosol into the chamber (e.g., Smith et al,

2020).

However, the vapor chamber method of pre-clinical ENDS use has substantial

limitations. Although rodents can move around freely, and in some preparations voluntarily

begin the aerosol presentation, the whole-body exposure method coats the interior of the

chamber and the rodent with nicotine-containing aerosol (Chellian et al., 2023). This nicotine

then undergoes further absorption through the derma as well as from grooming, confounding

measures of drug consumption and physiological impacts (Kogel et al., 2021; Lucci et al., 2020).

Furthermore, although a human puff typically lasts a few seconds at most (St. Helen et al., 2018),

in a vapor chamber, aerosol presentation is extended many times over the duration of a puff (up

to 100 s) while the vacuum system clears the chamber (Lallai et al., 2021; Moussawi et al.,

2020). This duration of aerosol inhalation may be stressful, which can change multiple

behavioral, physiological, and immunological processes (see Buynitsky & Mostofsky, 2009), and

lead rodents to modify their breathing to reduce extended involuntary exposure (Lallai et al.,

2021). Furthermore, some studies have failed to show strong control by the operant contingency,

finding a low and similar number of responses on the active manipulandum as compared to the

inactive manipulandum (Cooper et al., 2024; Marusich & Palmatier, 2023; Smith et al., 2020).

This issue may stem from the prolonged and diffuse presentation of the nicotine aerosol, making

discrimination of the causal response difficult (Bagdas et al., 2022). Finally, commonly used vapor chambers are also proprietary and cost prohibitive.

We have developed the Rodent Electronic Nicotine Delivery System (RENDS) to address the current limitations of preclinical ENDS models, provide a system with stronger face validity, and reduce barriers to research. The RENDS is a novel, non-invasive, non-proprietary, and relatively low-cost system for snout-only nicotine aerosol self-administration in freely moving rats. The system costs under $325 per chamber to retrofit four existing operant chambers. A custom-designed 3D-printed port records nose pokes and provides access to the aerosol. Here, we describe the RENDS system and present data to validate its function. We completed two main assessments. First, we confirmed that the e-cigarette aerosol cycles exclusively in the nose port, showing that RENDS provides snout-only access. To verify the operation of the nose port, we measured fine particulate matter less than 2.5 microns (PM2.5), found in e-cigarette aerosol and readily measured by air quality monitors (Li et al., 2020; Shearston et al., 2023), with and without the vacuum system of the RENDS in operation. Second, we showed that rats would robustly self-administer flavored e-cigarette aerosol, with concomitant high blood levels of cotinine, the major nicotine metabolite, and accompanying spontaneous somatic withdrawal (Malin et al., 1992). We demonstrated in a reversal design that rats only engaged in robust nose poking when pokes produced flavored nicotine aerosol and related stimuli. These metrics confirm that RENDS is a valid snout-only preclinical model of e-cigarette nicotine aerosol self-administration.

Validation of the RENDS

Subjects

We used a convenience sample to reduce animal numbers in the validation phase (NC3Rs, N.D.). Six rats (Charles River Laboratories), four Wistar, and two Long-Evans, were restricted to 85% of the free-feeding growth curve by post-session feeding. Rats lived in same-sex and same-strain pairs in standard plexiglas rodent enclosures residing in temperature-controlled colony rooms with a 12:12 hour light dark cycle. Experiments were conducted during the light part of the cycle. Colony rooms were located in an Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) certified facility. Water was freely available in the home cages. The Wistar rats, two male and two female, were approximately 170 days old at the start of the experiment, and are hereafter referred to as the nicotine subjects. Nicotine subjects participated in the self-administration, cotinine, and withdrawal assessments. The Long-Evans rats, one male, and one female, participated in withdrawal assessments at approximately 120 and 270 days old, respectively, and are hereafter referred to as the control subjects. Nicotine rats were 410 days old at the time of withdrawal assessments. All subjects were nicotine-naive but had previous experimental histories with reinforcement schedules of food delivery in operant chambers. All study procedures were approved by the Institutional Animal Care and Use Committee at Utah State University (Protocol #12626).

Apparatus and Materials

All RENDS system diagrams and plans for custom-made parts are freely available at our Open Science Framework (OSF) link: https://osf.io/x2pqf/?view_only=775b55435b8e428f98e6da384ef7889d. Current costs and parts needed for the RENDS are displayed in Table 1.

RENDS 4-chamber Set Up

Four identical operant chambers[1] (Med Associates, St. Albans, VT; ENV-008-B) housed in sound-attenuating cubicles (Med Associates; ENV-022MD) were retrofitted with the RENDS system (see Figure 1). Inside each chamber, two custom 3D printed nose ports (see below for detail) are situated on the left and right side of the front panel 0.5 cm (0.197 in.) above the floor grates. Nose port openings are 3 cm (1.18 in.) above the floor grates. A house light (Med Associates, ENV-215M-LED) is located at the top of the center panel. In each chamber, one nose port is designated as active and delivers nicotine aerosol, and the other is designated inactive and only records nose pokes. Which port is active and which is inactive is counterbalanced across chambers.

At the top of the active nose port in each chamber, silicon adapters attach the nose port to the e-cigarette and air circulatory system. Air comes into the system from an air compressor (Husky 20 Gallon Vertical Electronic-Powered Silent Air Compressor 3332013) through heat-resistant pneumatic tubing (Tailonz 6mm OD 4mm ID Polyurethane PU Air Hose Pipe Tube)[2]. An air regulator (CNBTR Multicolor Acrylic 3-30LPM LZQ-7 Oxygen Air Gas Flowmeter with Control Valve) allows adjustment of the air pressure to ensure the nicotine aerosol does not exit the nose port. From the air regulator, the pneumatic tubing extends to a vacuum generator (193480, Festo) and connects the top of the e-cigarette to the top of the nose port. A custom 3D printed e-cigarette holder (Figure 2),[3] designed in PrusaSlicer 2.9.0 , and printed in polylactic acid (PLA; Hatchbox, 1.75 MM filament) on a Prusa i3 printer, is mounted to the inner wall of the sound-attenuating cubicles approximately 25.4 cm (10 in.) from the outer chamber floor. The e-cigarette is activated by a solenoid (Relay Specialties 53761-82) that

---

[1] We retrofitted the RENDS to our existing Med Associates operant chambers, but with slight modifications it could be retrofitted to any similar operant chamber.

[2] One air compressor and vacuum can support up to six chambers fitted with RENDS.

[3] The holder is specific to a VooPoo Drag X (voopoo.com) but could be readily modified for other e-cigarettes.

manually extends to press the 'on' button of the e-cigarette[4]. Tubing (Cen-Tec Systems Quick Click Hose 1.25 in. diameter) attached to the end of the nose ports, secured with a stainless steel adjustable clamp (IDEAL-TRIDON 3/4-in to 1-3/4-in dia Stainless Steel Adjustable Clamp), extends to a custom 3D-printed vacuum tubing splitter, printed in PLA, which connects to the same type of tubing coming from the vacuum (Craftsman 4 gal Corded Wet/Dry Vacuum 120 V 5 HP)[5]. Air is exhausted through the vacuum, which is located by a building air exhaust or fume hood.

The specially designed 3D-printed nose port[6] (Figure 3), designed in Chitubox and printed in resin (Anycubic UV Photopolymer Resin for LCD 3D Printing, clear) on an Elegoo Saturn 8k printer, has two openings for reinforcer deliveries and can detect snout entry through an inset photo beam. The photobeam shines across the opening through recesses on each side of the port. Photobeams are constructed with IR break beam sensors (Electro Maker, 2167), perforated bread boards (Digikey, 1568-1652-ND), 220 OHM resistors (Virlros, VIPL080), 20 gauge speaker wire (Amazon, B09SH48KGK), and female and male 3-pin Molex connectors (Vetco Electronics, 61-403)[7]. Nicotine aerosol is delivered through a small opening in the top of the port, and then exhausted through four openings on the face of the port. In addition to the delivery of the e-cigarette aerosol, the port has a liquid reservoir to receive a reinforcer during pre-training or other uses (e.g., ethanol delivery). The liquid reservoir is filled through a ball pump needle (SHIBUN steel air inflation needle pin A8N3) attached to heat resistant Tygon®

---

[4] In our experience, activation longer than 2 s and more often than twice per min causes overheating of the e-cigarette.

[5] E-liquid condenses in the vacuum filter, so regular cleaning of the vacuum and filter, while wearing Personal Protective Equipment (PPE) to avoid nicotine exposure, is needed.

[6] The shape of the port and the resin material makes chewing less likely.

[7] The recesses do not open into the port, and the photo beam instead shines through the resin, because contact with the nicotine aerosol destroys the sensor. The recesses are plugged with clear resin corks as detailed on OSF.

tubing (S3 Non-DEHP 1/16"IDx3/10"OD). The needle is secured in the opening of the reservoir with industrial-strength adhesive (Eclectic E6000 PLUS). The tubing extends from the port and attaches to a 60 mL liquid syringe (BP). We deliver liquid into the reservoir using a syringe pump (PHM-200, Med Associates, St. Albans, VT), but in the absence of a pump, delivery could be achieved by manual depression of the syringe plunger.

E-Cigarette and Nicotine Solutions. We chose an e-cigarette (VooPoo Drag X mod pod; voopoo.com) and e-liquid to model current e-cigarettes and e-liquids favored by adolescents and young adults (Birdsey et al., 2023; Wang et al., 2020). Specifically, we used nicotine salt (nicotine hydrogen tartrate, SML1236; Millipore Sigma), which is easier to inhale than the harsher free-base form (Leventhal et al., 2020, 2021). E-cigarettes were set to 12 W and 1.2 Ω, as recommended for salt solutions (e.g., Rubery, 2022). Mesh coils were replaced every five days. We suspended the nicotine at 5 mg/mL with 5% mango flavoring (vaporvapes.com) in a base of 50/50 propylene glycol/vegetable glycerin (PG/VG; vaporvapes.com). We verified that the flavoring and PG/VG base had no detectable nicotine via gas chromatography/mass spectrometry (GC/MS) with a limit of detection of 0.015 mg/mL.

Validation. We used several pieces of apparatus and materials to validate the operation and function of the RENDS. To verify the RENDS contained the flavored nicotine aerosol in the nose port, we assessed air quality using a relatively low-cost and readily available monitor, the Zen (PurpleAir). The monitor was placed on the grate floor, equidistant from all sides of the chamber. The Zen has two sensors, and PM2.5 levels are reported as the average of the measurements from each sensor (i.e., the sum of PM2.5 levels for both sensors divided by two).

To verify that rats were ingesting meaningful levels of nicotine, blood serum was tested for the major nicotine metabolite cotinine. Nicotine subjects were anesthetized via isoflurane

during blood serum collection using a VetEquip V-1 tabletop system with a scavenging cube (item no. 931600), a 2L vented induction chamber (942102), and a CX-R circuit nose cone (921616). A F/AIR charcoal filter canister (Thermo Fisher Scientific catalog no. NC9989597) attached to the scavenging cube removed excess anesthetic gas during the procedure. The induction chamber and nose cone received anesthetic gas from the vaporizer (VAS incorporated, serial no. 104417) with a refillable isoflurane adapter and an oxygen tank which was regulated by a VetEquip O2 flow meter and Pro-star oxygen regulator gauge (model no. G250-150-540). Isoflurane gas ranged from 1-5% as needed to maintain anesthesia. To analyze the obtained blood serum for cotinine, we used a Calbiotech ELISA Assay (CO096D-100) with a standard range of 0-100 ng/mL and analytical sensitivity of 1 ng/mL on a Bio Tek ELx808 microplate reader according to the included ELISA kit standard protocol. Values outside the range of the standards were calculated using the equation from the standards curve with the minimum and maximum standard values.

To assess spontaneous somatic withdrawal symptoms, rats were placed individually in a 23 cm wide x 28 cm tall glass cylinder (Tabletops Unlimited 2L Glass Apothecary Jar). A sheet of plexiglass with a 5.08 cm (2 in.) diameter ventilation hole in the center, placed on top of the cylinder and secured by a 2.27 kg (5 lb) weight, served to keep rats inside. An iPad Pro (model no. ML0G2LL/A) camera, located on a tripod 41.91 cm (16.5 in) away from the cylinder, was used to record withdrawal assessments.

Procedure

RENDS Apparatus Assessment

We measured PM2.5 particulate matter in three separate conditions in the closed operant chamber. In all conditions, air quality was assessed for 10 mins. We first measured air quality in

the chamber without the e-cigarette or vacuum system operating (room air). This assessment provided a baseline measure of air quality. For the following two conditions, a 2-s e-cigarette aerosol presentation occurred each min. In the first of these conditions, the vacuum system was on, and in the second of these conditions, the vacuum system was off. Between each condition, the air quality monitor was removed from the chamber for 10 mins to allow the sensors to re-adjust before the next condition. We conducted this same assessment (baseline room air, puffs with vacuum system on, puffs with vacuum system off) on six consecutive days at approximately the same time. Air quality measurements are reported as mean levels of PM2.5 across the 10-min tests for each assessment.

Self-Administration

Behavior.

The RENDS system produces a variety of sounds due to the operation of the vacuum and the periodic refilling of the air compressor. Therefore, nicotine subjects were first acclimated to the RENDS by placing their home cages in a hallway adjacent to the experimental room for 1 hr with the RENDS system running.

The apparatus was tested prior to each daily experimental session. Sessions began with a 1-min chamber blackout, during which nose pokes had no programmed consequences and visual stimuli were off. Sessions ended after a maximum of 85 mins. Nose pokes with a duration of at least 20 ms were counted except as noted during pre-training.

Pre-Training. Nicotine subjects underwent pre-training with a 10% (w/v) sucrose solution to hold their snout in the active nose port. All sessions during pre-training ended after 40 0.09-mL sucrose deliveries (2.84 s activation of the syringe pump) into the liquid reservoir on a Variable Time (VT) 90 s schedule using a Fleshler and Hoffman (1962) distribution. During the

two sessions of magazine training, the stimulus light over the port was lit during the sucrose delivery. During the one session of autoshaping (Brown & Jenkins, 1968), the house light and the stimulus light above the nose port were lit for 10 s, followed by response-independent sucrose presentation. Any nose pokes during stimulus presentations terminated the trial and produced the immediate delivery of sucrose.

Next, the reinforcement schedule requirements were gradually increased and rats were trained to hold their head in the port across fifteen sessions. These schedules started with a Fixed Ratio (FR) 1, in which each response produced the sucrose reinforcer, then progressed through variable ratio schedules, in which the reinforcer was delivered after an unpredictable number of responses with a certain mean (Ferster & Skinner, 1957) starting with a Variable Ratio (VR) 1.5 and moving ultimately to a VR3. After two sessions in which all available reinforcers were obtained within the maximum session time, the required duration of the nose poke was gradually increased both within and across sessions to 2 s to ensure the rats could keep their snouts in the port for the duration of the eventual nicotine aerosol presentation. The VR3 schedule began once rats reliably earned all reinforcers with the 2-s nose-poke requirement. Once the VR3 schedule began, the 2-s nose-poke requirement was removed and the minimum duration for a nose poke to be recorded was again 20 ms.

Throughout pre-training and the rest of the experiment, at the start of each trial, the house light and stimulus lights illuminated, and after the schedule requirement was met, the stimulus lights extinguished and the reinforcer was delivered; the house light turned off at the end of reinforcer delivery. There was a 30-s inter-trial interval (ITI), during which all lights were off and nose pokes had no consequences, after each reinforcer delivery. The procedure is modeled on that used in IV nicotine self-administration (e.g., Pittenger et al., 2016).

Experimental Conditions. Following pre-training, the four nicotine subjects completed five experimental conditions to examine nicotine aerosol self-administration. Here, we describe and present data from three of these conditions: VR2 baseline, extinction, and VR2 return to baseline[8]. During self-administration, flavored nicotine aerosol was presented for 2 s in the nose port on a VR2 schedule with all details as in pre-training. Sessions ended after 75 deliveries of nicotine aerosol or 85 min. This condition was in effect for 50 sessions. For the extinction condition, the RENDS system and all chamber stimuli were off and nose pokes had no scheduled consequences (i.e., nicotine aerosol was not available). Nose pokes in either port continued to be recorded. Extinction was in effect for 10 sessions. During the VR2 return to baseline period, which was identical to the VR2 baseline condition, nicotine aerosol was again available for active nose pokes; the VR2 return to baseline was in effect for 25 sessions.

Blood Levels of Cotinine. We analyzed blood serum samples for the major nicotine metabolite cotinine by ELISA assay. Blood serum samples were collected under anesthesia 20 min post experimental sessions via lateral saphenous vein puncture (Van Herck et al., 2001)[9]. Estimates for cotinine levels for e-cigarette users range from 100-300 ng/mL or higher, with an average around 200 ng/mL (Rapp et al., 2020; Scherer et al., 2022; Zhang et al., 2024). We obtained blood samples after session 20 and 43 (M12 & F22) and 21 and 44 (M11 & F21) of VR2 baseline, and after session 10 of extinction (F21 & F22). Males did not experience blood draws during extinction as they had adverse reactions to the anesthesia.

---

[8] These conditions were not contiguous; two other conditions were completed, one between VR2 baseline and extinction and one between extinction and VR2 return to baseline, but are not described nor data presented here. We also had an apparatus error early in the initial baseline. Therefore we do not present data during acquisition or transitions. Rats continued self-administration beyond the data reported here.
[9] Other details are available in supplemental files on OSF.

Spontaneous Somatic Withdrawal. We based the spontaneous somatic nicotine withdrawal symptom assessment on a combination of previous procedures (Besheer & Bevins, 2003; Frie et al., 2023; Malin et al., 1992). One day before withdrawal assessments, all subjects were acclimated to the observation cylinders for 10 min. During the withdrawal assessment, nicotine rats were placed in the observation cylinders and recorded for 10 min directly before a self-administration session, approximately 22 hr after the last session. This assessment period allowed for 1) data collection during the longest duration of nicotine abstinence between sessions and 2) an optimal opportunity to observe somatic symptoms of spontaneous withdrawal at their peak following the termination of nicotine consumption in rats (approximately 17 to 23 hr; Malin et al., 1996, 1998). Control rats experienced the same assessment as the nicotine rats at approximately the same time of day. Withdrawal assessments occurred roughly two months after the last condition depicted in Figure 6, following continued daily sessions of self-administration.

After withdrawal assessments were recorded, each video was assigned to two individual coders for scoring. Teeth chattering, writhes or gasps, shakes, piloerection, yawns, dyspnea, and ptosis were all coded as target somatic symptoms of withdrawal (Frie et al., 2023; Malin et al., 1992). We developed a code book featuring the operational definitions and examples of each symptom for review before scoring, which can be found on OSF. We used partial interval scoring (i.e., noting either yes or no for the occurrence of each symptom) during one-min intervals throughout the 10 min assessment period. Interobserver agreement (IOA) was calculated by dividing minute interval agreements by the sum of agreements and disagreements. Final withdrawal scores were found by averaging the two ratings (Frie et al., 2023).

Data Analysis

The majority of papers published in *JEAB* follow an analysis strategy of presenting individual subject data for visual inspection as well as performing inferential statistics (Kyonka et al., 2019), and we followed this convention. For all analyses, we relied mainly on visual inspection of individual subject data (Perone, 1991), but when possible, we also included inferential tests to further delineate findings and to provide estimates of effect sizes[10]. Data were collapsed across sex for each analysis due to the small sample size. Prior to completing inferential statistics, we conducted Shapiro-Wilk tests for normality (Shapiro & Wilk, 1965). All analyses and data visualizations were conducted in GraphPad Prism (version 10 for Mac OS, Boston, MA). Prism files are found on OSF.

Our first analyses focused on the apparatus assessment of PM2.5 levels across conditions of room air, puffs with the vacuum system on, and puffs with the vacuum system off. All data with the exception of room air passed normality testing; room air, $W = 0.50$, $p < .001$. Therefore, for the apparatus assessment, we compared PM2.5 levels in the chamber with room air and puffs with the vacuum system on using a nonparametric Wilcoxon matched-pairs signed rank test. In comparing PM2.5 levels for puffs with the vacuum system on and off, a paired-samples *t* test was performed. We report Cohen's *d* effect sizes with conventions described as follows: small effect = .2, moderate effect = .5, and large effect = .8 or greater (Cohen, 1988); however, these conventions are generally noted as arbitrary and should be treated as guidelines (Lakens, 2013).

Our second set of analyses focused on self-administration assessments. Specifically, we examined nose pokes in active and inactive ports across baseline VR2 sessions, extinction, and return to baseline VR2 conditions, collapsed across sex. We note any observed sex differences via visual analysis of the disaggregated data (see Odum et al., 2024). We first show

---

[10] With inferential statistical analysis of small samples, we run the risk of a Type II error rather than Type I error (Sullivan et al., 2016). In other words, with small sample sizes, we risk failing to find an effect when there may be one, rather than finding an effect where there is none.

representative cumulative records for each subject on the last session of each condition. We then show the total number of active and inactive nose pokes for the last six sessions of each condition for individual subjects. With the exception of active nose-poke responses during extinction, all data from the last six sessions for each condition were non-normally distributed: baseline VR2 active nose pokes ($W = .74$, $p < .0001$); baseline VR2 inactive nose pokes ($W = .84$, $p = .001$); extinction active nose pokes ($W = .98$, $p = .85$); extinction inactive nose pokes ($W = .77$, $p < .001$); return to VR2 baseline active nose pokes ($W = .68$, $p < .001$); return to baseline VR2 inactive nose pokes ($W = .80$, $p = .001$). Therefore, we first transformed data by ranks and conducted a 2 (nose pokes: active vs. inactive) by 3 (condition: baseline VR2, extinction, return to baseline VR2) nonparametric-approximate mixed ANOVA (a two-way nonparametric test for repeated measures comparable to a Friedman's test with interactions; Conover & Iman, 1981; Friedman, 1937)[11]. Bonferroni multiple comparison tests were used to examine more specific differences in the ranked data[12]. We report effect sizes as η^2 with the following conventions: small effect = 0.01, medium effect = .06, and large effect = .14 or greater (Adams & Conway, 2014; Cohen & Cohen, 1983).

For the next analyses, we examined the cotinine and withdrawal data. Because the cotinine data were non-normally distributed ($W = .82$, $p = .032$), we computed a Spearman's rank-order correlation between the number of puffs earned for the VR2 baseline and extinction sessions and resulting cotinine levels for those sessions. We report Spearman's ρ as the effect size. Finally, we compared withdrawal scores, collapsed across sex, for the nicotine and control subjects using an independent sample t-test. We report Cohen's d for effect size, using the

---

[11] Transforming the data into rank orders to reflect the non-normal distributions did not change the outcome of the results. A parametric ANOVA on the unranked data produced the same results; these results can be found in Prism files on OSF.
[12] We give a subset of these tests in this report. All follow up tests can be found on OSF.

conventions we described above in the *t*-test analyses for air quality; effect size conventions for

ρ are the same as Cohen's *d*.

Results

Apparatus Assessment

The level of PM2.5 particles in the chamber air with puffs with the vacuum system on

was similar to room air level with no puffs (see Figure 4). Specifically, in the room air condition,

PM2.5 was very low ($M = 0.17$ µg/m³, $SD = 0.41$). The PM2.5 level for puffs with the vacuum

system on ($M = 2.58$ µg/m³, $SD = 2.11$) did not differ from room air with no puffs ($n = 12$, $W =$

15, $p = .063$). The means for the room air with no puffs and vacuum system on with puffs were

both well below the cut-off for the highest standard for air quality (see Figure 4 note). Finally, in

the condition with puffs with the vacuum system off, PM2.5 was extremely high ($M = 2,631.5$

µg/m³, $SD = 241.6$) and over 10 times the level considered hazardous (see Figure 4 note). Mean

PM2.5 levels were significantly different between puffs with the vacuum system on and off ($t(5)$

$= 26.66$, $p < .0001$).

Self-Administration

Figure 5 shows that the cumulative number of active port nose pokes during the

self-administration VR2 baseline and return to VR2 baseline sessions far exceeded that of the

number of inactive port nose pokes for all rats. During baseline and the return to baseline, active

port nose pokes typically started 5-10 mins after the beginning of the experimental session and

occurred at a high constant or increasing rate. Furthermore, when active port nose pokes no

longer produced the flavored nicotine aerosol and stimuli in the extinction condition, active and

inactive nose pokes occurred at a similar low rate across the session. Male rats made more

inactive nose pokes than female rats during baseline and return to baseline. The number of nose

pokes in the active port, as well as the difference between nose pokes in the active and inactive ports, was relatively similar during the baseline and return to baseline sessions.

Figure 6 shows the total number of active and inactive nose pokes for the last six sessions of the self-administration VR2 baseline, extinction, and return to VR2 self-administration conditions. Nose poking differed by condition, as shown by a significant main effect of condition, $F(2, 69) = 29.87$, $p < .0001$, $\eta^2 = 15.24$. There was also a significant main effect of nose pokes, $F(1, 69) = 170.8$, $p < .0001$, $\eta^2 = 37.69$, showing that the total number of active nose pokes greatly exceeded that of inactive nose pokes across conditions. Additionally, there was a significant nose poke by condition interaction $F(2, 69) = 32.25$, $p < .0001$, $\eta^2 = 14.23$, showing that active and inactive nose pokes were affected differently across conditions.

The total number of active nose pokes was high and consistent across the sessions of baseline and return to baseline conditions. The average across all rats was 147.65 active nose pokes, which represents a ceiling due to the limit of 75 reinforcers. In these sessions, there were no differences in the number of active nose pokes for male and female rats. In follow-up tests, active nose pokes ($M = 148.5$, $SD = 4.065$) were significantly greater than inactive nose pokes ($M = 17.08$, $SD = 17.14$) during the VR2 baseline (p < .0001) as well as for the VR2 return to baseline (active nose pokes, $M = 146.8$, $SD = 6.53$; inactive nose pokes, $M = 20.63$, $SD = 24.32$; $p < .0001$). In extinction, active nose poking fell drastically ($M = 15.29$, $SD = 6.011$) to 10% of the number of active nose pokes during baseline; active and inactive nose pokes ($M = 15.29$, $SD = 16.43$) did not significantly differ during extinction ($p = .31$). Inactive nose pokes remained relatively low and unchanging across conditions, with 17.77 inactive nose pokes on average across all conditions. Male rats made more inactive nose pokes than females, with M12 in particular showing a higher and more variable number of inactive port nose pokes. The ratio of

active to inactive nose pokes, averaged across baseline conditions, was 6:1 (M1), 3:1 (M2), 76:1 (F1), and 81:1 (F2); averaged across rats, the ratio was 42:1.

Figure 7 shows a strong positive correlation between the number of puffs earned and cotinine levels for nicotine subjects during the VR2 baseline (Spearman's ρ = .84, p = .01). This relation confirms that as the number of puffs earned increased, blood levels of cotinine increased. Blood serum from nicotine subjects had high cotinine concentrations during the VR2 baseline condition. Specifically, the average cotinine concentration across males and females was 153.75 ng/mL. The range of cotinine during the VR2 baseline was 12.12 to 214.39 ng/mL (the highest level of cotinine that could be calculated with the ELISA kit). During extinction, cotinine levels for female subjects were very low (M = 1.63).

Figure 8 shows that scores on the withdrawal scale were substantially higher for nicotine rats than control rats. Specifically, mean scores were significantly different between nicotine (M = 31.13, SD = 3.01) and control subjects (M = 7.00, SD = 1.41; $t(4)$ = 10.31, p < .0005). The difference in withdrawal scores between nicotine and control subjects was large, d = 10.26. Female nicotine rats had somewhat lower withdrawal scores than males. Mean IOA across all symptoms was acceptable at 80.36%. Withdrawal scores for specific symptoms for all subjects can be found on OSF.

Discussion

We described and validated the RENDS, a novel preclinical system for nicotine aerosol self-administration, across two main assessments: apparatus operation and self-administration. Our goal was to advance preclinical research on e-cigarette use with a low-cost non-proprietary laboratory animal model with high face validity. Specifically, we found that the system sequestered nicotine aerosol in the nose port, shown by similar levels of PM2.5 particulates

between the air in the operant chamber (room air) without any e-cigarette puffs and the chamber air with puffs and the vacuum system in operation.[13] We also found that rats reliably self-administered nicotine aerosol through the nose port, demonstrated by a high number of active nose pokes, cotinine levels, and withdrawal symptoms. Below we describe and discuss these findings in turn.

To determine whether RENDS functions as intended, by sequestering nicotine aerosol in the nose port, we evaluated the level of PM2.5, extremely small particulates produced by e-cigarettes (e.g., Li et al., 2020; Shearston et al., 2023). We found no difference between the levels of PM2.5 for baseline room air compared to PM2.5 levels when the vacuum system was on. This result verifies that when the RENDS system is in operation, e-cigarette PM2.5 particles do not enter the chamber at a rate above that found in room air. Thus, to consume nicotine with the RENDS, rats must access the aerosol inside the nose port. We also found, unsurprisingly, that when the vacuum system was not in operation and the aerosol filled the chamber, as in vapor chamber models, PM2.5 levels were significantly higher. Together, these results highlight that RENDS provides access to inhaled nicotine aerosol through snout-only contact with the port, which not only increases face validity but eliminates whole-body contamination issues with vapor chamber models (Chellian et al., 2023; Kogel et al., 2021; Lallai et al., 2021; Lucci et al., 2020). Furthermore, it documents that PM2.5 levels in a closed chamber with one 2-s puff per min for 10 min reach levels over 100 times higher than considered hazardous by the USEPA (2024).

---

[13] Shelton and Nicholson (2022) describe a nose-only chamber for aerosolized *opioid* self-administration in rats. However, this chamber was as yet not verified to sequester the aerosol in the port, opioid levels were not assessed, and rats received food training in between each opioid-self administration condition.

Our second form of validation of the RENDS focused on self-administration. In the behavioral assessment, we examined nose poking in the active port for flavored nicotine aerosol when it was available (VR2 baseline), when access was no longer available (extinction), and when nicotine aerosol was again available (VR2 return to baseline). This rigorous reversal design showed that overall, rats robustly self-administered nicotine aerosol when available (average 147.65 active nose pokes per session), but showed minimal active nose poking when nicotine aerosol and associated cues were not available (average 15.29 per session during extinction). Furthermore, nose pokes occurred at a far higher rate in the active port, which produced nicotine aerosol, than the inactive port, which did not produce nicotine aerosol (average ratio of 42:1 across rats and baseline conditions). These findings are clear both in cumulative records of nose poking across time in the last session of each condition (Figure 5) and in total nose pokes per session across the last 6 sessions of each condition (Figure 6). Furthermore, these findings demonstrate much stronger behavioral control by the response contingencies compared to the vapor chamber full body exposure method (e.g., Cooper et al., 2024; Marusich & Palmatier, 2023; Smith et al., 2020).

Although prior research has found some evidence of discrimination between active and inactive responses with nicotine aerosol self-administration in the vapor chamber method, our study is the first to show robust discrimination. In previous work, response rates were generally low on both the active and inactive operanda (e.g., Cooper et al., 2024; Marusich & Palmatier, 2023; Smith et al., 2020). For example, Smith et al. (2020) found 20 or fewer active lever presses across 1 hr sessions, and a similar or higher number of inactive lever presses. In a study with e-liquid composition similar to that in the present research, but with mice in 2-hr sessions in vapor chambers, Cooper and colleagues (2024) found less than 15 active nose pokes (7.5/hr)

with green-apple flavored 6 mg/mL nicotine salt. Furthermore, mice first had involuntary aerosol pre-exposure to induce nicotine dependence and continued to receive response-independent puffs during sessions if there was a long pause in nose poking. Additionally, in these studies a large percentage of mice (> 30%, Cooper et al., 2024; > 75%, Henderson et al., 2024) were excluded from the study for maintaining a less than 2:1 ratio of active:inactive nose pokes. In the present study, rats averaged over 105 active pokes/hr and a ratio of active:inactive pokes of over 40:1 with no prior nicotine exposure or response-independent puffs, and 100% of subjects were included in the study and vigorously self-administered nicotine aerosol.

There may be several explanations for the difference in the overall number of active responses as well as better discrimination between active and inactive responses shown with RENDS compared to the vapor chamber model. First, we used the salt form of nicotine and most other prior studies used the free-base form (e.g., Smith et al., 2020; Marusich & Palmatier, 2023); however, this difference seems an unlikely explanation because Cooper et al. (2024) used the salt form and still found low levels of active responses. Furthermore, we used flavored nicotine aerosol and most other studies have used unflavored; however, this difference also seems an unlikely reason because studies using flavored nicotine with the vapor chamber method have also found a low number of active responses and poor discrimination (e.g., Cooper et al., 2024; Marusich & Palmatier, 2023). Additionally, poor discrimination and low active response rates have been found using the vapor chamber method with both rats and mice (e.g., Cooper et al., 2024; Smith et al., 2020), so the species seems an unlikely cause for the differences as well.

There are two more likely reasons for the robust active responses with the RENDS compared to the vapor chamber method. First, compared to the vapor chamber, there is greater temporal and spatial contiguity between the active response and aerosol delivery. With RENDS,

the location of the response that causes the aerosol delivery is in the same place as the source of the aerosol delivery, so the aerosol delivery is highly contiguous with the nose poke which produced it. In contrast, in the vapor chamber method, the response that produces the aerosol is removed from where the aerosol is delivered, and there is a delay from aerosol initiation to when it reaches the rodent. In general, delays between when a response occurs and a consequence is delivered weaken the response and reduce the discriminability of the contingent relation (Lattal, 1975, 1995). Indeed, Henderson et al. (2024) found that mice that did not stand close to where the nicotine aerosol entered the chamber did not acquire nose poking. A second reason for less robust self-administration in the vapor chamber technique is that the manner and length of the nicotine aerosol presentation may be aversive. The aerosol in the chamber may plausibly irritate the eyes, and the effects of higher nicotine doses are aversive (e.g., Koffarnus & Winger, 2015; Shoaib & Stolerman, 1995). The presentation of the aerosol lasts up to 100 s and rats may modify their breathing to intake less aerosol (Lallai et al., 2021). In contrast, in the RENDS, the aerosol only contacts the snout, the puff duration (2 s) is similar to that of human e-cigarette users, and rats can discontinue inhaling at any point during puffs.

Despite the advantages of strong contiguity between the response and consequence in the RENDS, this method also makes it impossible to distinguish between nicotine seeking and nicotine consumption. Specifically, subjects engage in the same response (i.e., active port nose poking) to both earn and consume the nicotine aerosol. These goal-directed and consummatory responses could individually provide enlightening insights into the fundamental nature of nicotine aerosol self-administration. For example, rats could earn aerosol presentations by pressing a lever placed underneath or beside the port, and consume the presentations by placing their snout in the port, much like with lever pressing for food-maintained behavior in which the

operandum and reinforcer delivery are spatially separated. Investigators may want to consider this sort of method of parsing these responses in the future.

Rats who self-administered nicotine aerosol through the RENDS had high blood levels of cotinine (the major nicotine metabolite). Thus, not only were the rats engaging in robust nose poking in the active port, they were also consuming biologically relevant levels of nicotine, similar to that obtained in preclinical models of IV nicotine self-administration (e.g., Shoaib & Stolerman, 1999) as well as with humans with daily tobacco and e-cigarette use (e.g., Rapp et al., 2020; Schroeder et al., 2014). Furthermore, there was a direct relation between the number of nicotine aerosol puffs and cotinine: the more puffs earned, the higher the cotinine level. Women using e-cigarettes have higher cotinine levels than men (e.g., Park & Choi, 2019), but we were not able to examine preclinical sex differences in cotinine with nicotine aerosol self-administration due to our small sample size and ceiling effect. Future research in this area should remedy these limitations (see Odum et al., 2024). There is a surprising dearth of preclinical research on sex differences in voluntary nicotine use in general (Chellian et al., 2023). However, Barrett et al. (*in press*) and Chellian et al. (2024) found that female rats self administered more IV nicotine than male rats.

We found spontaneous somatic symptoms of nicotine withdrawal following self-administration of nicotine aerosol with the RENDS, which to our knowledge is the first in the literature. Nicotine rats had substantially higher withdrawal scores relative to control rats. The difference in withdrawal symptoms between the nicotine and control subjects replicates the only other finding of withdrawal in the literature with self-administered nicotine aerosol to date (Smith et al., 2020), which was precipitated by the nicotine antagonist mecamylamine. One potential reason for the robust spontaneous withdrawal found here is the length of nicotine

aerosol self-administration before withdrawal testing (146 daily sessions). We did not evaluate withdrawal early in the self-administration condition. It will be interesting and important to examine the development of withdrawal across acquisition and maintenance conditions of nicotine aerosol self-administration.

The long-term exposure to nicotine described in this report demonstrates that our system is particularly advantageous for chronic self-administration of nicotine aerosol. Specifically, other commonly used techniques (e.g., IV self administration) have been challenged to evaluate nicotine self-administration for long durations due to catheter issues (Suarez et al., 2024). Catheters used in IV self-administration are difficult to retain over time due to loss of patency and growth of rodents. Catheters are also challenging to implant for smaller rodents like mice and adolescent rats (Belluzzi et al., 2005; Pogun et al., 2017). Our system, however, is capable of maintaining consistent consumption of nicotine aerosol over a long time, demonstrated by self-administration by 100% of nicotine subjects across more than 200 daily sessions. In contrast, for IV catheters, 88% patency for 46 days is considered exceptional (Suarez et al., 2024). Additionally, the RENDS could be used with smaller rodents by decreasing the size of the port and lowering placement on the front panel. Thus, the RENDS, both in design and methodology, may serve as a practical and instrumental avenue for novel longitudinal investigations of nicotine aerosol self-administration in rodents.

Although we have refined the RENDS over many prototypes, the system and methodology could still be improved. For example, one limitation of the present validation was reliance on a small convenience sample of subjects of different strains and ages. This strategy was a conscious choice to reduce animal numbers in line with the three R's of research (replacement, reduction, and refinement; NC3Rs, N.D.). However, future investigations in this

area should increase the number of subjects as well as include matched controls. In addition, during experimental conditions, we limited the number of aerosol presentations available in a session to 75. Our reasoning was to reduce the likelihood of subjects consuming high, potentially aversive, doses of nicotine. However, the maximum number of aerosol presentations was reached in most sessions, usually well before the maximum session time, leading to a ceiling effect. Future research in this area should increase the number of available nicotine aerosol presentations within a session.

Although rats robustly self-administered nicotine aerosol, unlike with IV self-administration, each reinforcer presentation could differ in the amount of nicotine based on how long and intensely the subjects inhaled the aerosol. Therefore, we measured blood levels of cotinine, which were on average high. However, without cotinine levels, we are unable to document the amount of nicotine rats self-administer. Blood collection is an invasive process, requiring rats be either anesthetized or restrained, both of which create complications and could affect self-administration and physiological data. Therefore, an alternative method for evaluating cotinine levels would be beneficial. As one option, cotinine can be detected in rodent urine via ELISA (e.g, Calbiotech CO096D-100), which can be collected relatively easily (Kurien et al., 2004), and could provide an alternative to blood collection.

Our methodology demonstrates the strong reinforcing function of the flavored nicotine aerosol, but we did not evaluate to what extent the flavor or nicotine were responsible for the effects. Our goal was to provide a model of human e-cigarette use, because flavoring plays a powerful role in ENDS initiation and use (e.g., Audrain-McGovern et al., 2016; Baker et al., 2021; DeVito & Krishnan-Sarin, 2018; Leventhal et al., 2019, 2020; Zare et al., 2018). However, nicotine has complex functions in maintaining behavior: it can serve as a primary reinforcer

(Chaudhri et al., 2007; Donny et al., 1998), imbue associated stimuli with conditioned

reinforcing function (Wilkinson & Bevins, 2008), and enhance the rewarding properties of other

stimuli (Barrett & Bevins, 2012; Barrett & Odum, 2011; Bevins & Palmatier, 2004). These latter

processes could enhance the rewarding value of flavor and nicotine-paired cues, potentially

increasing self-administration. Both flavor and cues can also maintain self-administration in the

absence of nicotine (e.g., Barrett & Odum, 2011; Cooper et al., 2023). Therefore, we are unable

to delineate the separate roles of nicotine, flavoring, and cues in producing the robust

self-administration found with the RENDS. Whether flavor should be included in an e-cigarette

protocol will depend on the goals of the research. Future research should attempt to delineate the

roles of the complex stimuli present in ENDS use now that we have established a system for

doing so.

An additional consideration for investigators moving forward is the method of

pre-training employed in this report. Although our procedure is modeled after those commonly

used in the drug self-administration literature and nicotine aerosol in particular (e.g., Abraham et

al., 2023; Pittenger et al., 2016; Marusich & Palmatier, 2023), there are adjustments to

pre-training that reduce associations between the active manipulandum and food. For example,

subjects can be food trained on both response manipulanda (i.e., both the eventual active and

inactive) as in Barrett and Bevins (2013). This procedure ensures that responding on the active

manipulandum following pre-training is explained solely by the contingency between the

manipulandum and reinforcer, rather than disproportionate pre-training experience and

association with food on just one manipulandum. This particular pre-training methodology could

be implemented in our procedure to increase rigor. Specifically, because subjects would have

experience working for sucrose in both nose ports, disproportionate nose poking in the active

port would reflect only the contingencies between nose poking in that port and the nicotine aerosol. Because our experiment continued for many sessions, it seems unlikely that the differential pre-training affected the long-term results, but non-differential pre-training would be an improvement regardless.

There are several future directions to note given that the robust data described here have provided comprehensive validation of the RENDS. Because our system addresses many concerns of other nicotine aerosol self-administration models, the RENDS can be used to evaluate the effects of long-term (chronic) and more face valid consumption of nicotine aerosol. The RENDS could also be useful in streamlining methodologies used in nicotine aerosol self-administration research. Prior research has generated mixed results, such as varying rates of self-administration and discrimination between active and inactive manipulanda (see Marusich & Palmatier, 2023 for discussion), that could be potentially explained by differential procedures and components of nicotine aerosols. With the high experimental control and discrimination between ports we have demonstrated with the RENDS, manipulation of other procedural details could generate valuable insights into the intricacies of self-administration of nicotine aerosol in preclinical analogs and clarify the mixed findings of past research.

This report continues prior efforts to make research more accessible (e.g., Aguiar et al., 2020; Buscher et al., 2020; Escobar et al., 2022; Escobar & Pérez-Herrera, 2015; Gurley et al., 2019; Rizzi et al., 2016). For example, Escobar and Pérez-Herrera (2015) created an interface for operant research, in which low-cost equipment and freely-accessed prototyping platforms allow for the increased accessibility to otherwise costly hardware and software systems. Recently, Escobar and colleagues (2022) developed an inexpensive 3D-printed operant chamber, plans for which are freely available, as an alternative to standard commercial chambers. Additionally,

Buscher et al. (2020) developed a standardized operant chamber that incorporates inexpensive and open-sourced behavioral and electrophysiology systems using Raspberry Pi technology. Like these advancements and others, the RENDS offers a more accessible, practical, and cost-effective alternative to expensive commercial systems and equipment.

In sum, the RENDS provides a validated low-cost system for snout-only e-cigarette aerosol inhalation in rodents. The plans for the custom-created 3D-printed components are freely available on OSF. Our goal is to further open the possibilities of preclinical research into ENDS with robust methods to promote regulation, prevention, and cessation strategies. It has become increasingly crucial to develop models like the RENDS to investigate nicotine aerosol self-administration, as nicotine consumption is on the rise, even as the long-term impacts and harms associated with ENDS use are not completely understood (Baldassarri, 2020; Shehata et al., 2023; Vu et al., 2024). The RENDS also enables research into the basic mechanisms that make this relatively new and pernicious form of nicotine use so appealing. Thus, we hope to foster continued research on this complex drug with widespread use dating back over 12,000 years (Duke et al., 2022).

References

Abraham, A. D., Wiley, J. L., & Marusich, J. A. (2023). Experimenter administered Δ9-THC decreases nicotine self-administration in a rat model. *Pharmacology Biochemistry and Behavior*, *231*, 173632. https://doi.org/10.1016/j.pbb.2023.173632

Adams, M. A., & Conway, T. L. (2014). Eta squared. In A. C. Michalos (Ed.), *Encyclopedia of quality of life and well-being research.* Springer*, 1995-1996.* https://doi.org/10.1007/978-94-007-0753-5_918

Aguiar, L. A. A., de Vasconcelos, N. A. P., Tunes, G. C., Fontenele, A. J., de Albuquerque Nogueira, R., Reyes, M. B., & Carelli, P. V. (2020). Low-cost open hardware system for behavioural experiments simultaneously with electrophysiological recordings. *HardwareX*, *8*, e00132. https://doi.org/10.1016/j.ohx.2020.e00132

Alanazi, A. M. M., Alqahtani, M. M., Pavela, G., Ford, E. W., Leventhal, A. M., & Hendricks, P. S. (2020). Mental health and the association between asthma and e-cigarette use among young adults in the United States: A mediation analysis. *International Journal of Environmental Research and Public Health, 17*(23), 8799. https://doi.org/10.3390/ijerph17238799

Audrain-McGovern, J., Strasser, A. A., & Wileyto, E. P. (2016). The impact of flavoring on the rewarding and reinforcing value of e-cigarettes with nicotine among young adult smokers. *Drug and Alcohol Dependence, 166*, 263-267. https://doi.org/10.1016/j.drugalcdep.2016.06.030

Bagdas, D., Kebede, N., Zepei, A. M., Harris, L., Minanov, K., Picciotto, M. R., & Addy, N. A. (2022). Animal models to investigate the impact of flavors on nicotine addiction and dependence. *Current Neuropharmacology, 20*(11), 2175–2201.

https://doi.org/10.2174/1570159X20666220524120231

Baker, A. N., Wilson, S. J., & Hayes, J. E. (2021). Flavor and product messaging are the two most important drivers of electronic cigarette selection in a choice-based task. *Scientific Reports, 11,* 4689. https://doi.org/10.1038/s41598-021-84332-4

Baldassarri S. R. (2020). Electronic cigarettes: Past, present, and future: What clinicians need to know. *Clinics in Chest Medicine, 41*(4)*,* 797–807. https://doi.org/10.1016/j.ccm.2020.08.018

Barrett, S. T., & Bevins, R. A. (2012). A quantitative analysis of the reward-enhancing effects of nicotine using reinforcer demand. *Behavioural Pharmacology, 23*(8), 781-789. doi: https://doi.org/10.1097/FBP.0b013e32835a38d9

Barrett, S. T., & Bevins, R. A. (2013). Nicotine enhances operant responding for qualitatively distinct reinforcers under maintenance and extinction conditions. *Pharmacology Biochemistry and Behavior, 114-115*, 9-15. https://doi.org/10.1016/j.pbb.2013.10.012

Barrett, S. T., McNealy, K. R., Ramirez, H., Flynn, A., & Bevins, R. A. (*in press*). Pavlovian conditioning with the internal stimulus effects of nicotine heightens later nicotine taking with variation by dose and sex. *Scientific Reports.*

Barrett, S. T., & Odum, A. L. (2011). The effects of repeated exposure on the reward-enhancing effects of nicotine. *Behavioural Pharmacology*, *22*(4), 283-290. https://doi.org/10.1097/FBP.0b013e3283473c25

Belluzzi, J. D., Wang, R., & Leslie, F. M. (2005). Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. *Neuropsychopharmacology, 30*(4), 705–712. https://doi.org/10.1038/sj.npp.1300586

Benowitz, N. L., Hukkanen, J., & Jacob, P., 3rd (2009). Nicotine chemistry, metabolism, kinetics

and biomarkers. *Handbook of Experimental Pharmacology*, *192,* 29–60.

https://doi.org/10.1007/978-3-540-69248-5_2

Besheer, J., & Bevins, R. A. (2003). Impact of nicotine withdrawal on novelty reward and related

behaviors. *Behavioral Neuroscience, 117*(2), 327–340.

https://doi.org/10.1037/0735-7044.117.2.327

Bevins, R. A., Barrett, S. T., Huynh, Y. W., Thompson, B. M., Kwan, D. A., & Murray, J. E.

(2018). Experimental analysis of behavior and tobacco regulatory research on nicotine

reduction. *Journal of the Experimental Analysis of Behavior, 110*(1), 1–10.

https://doi.org/10.1002/jeab.439

Bevins, R. A., & Palmatier, M. I. (2004). Extending the role of associative learning processes in

nicotine addiction. *Behavioral and Cognitive Neuroscience Reviews, 3*(3), 143-158.

https://doi.org/10.1177/1534582304272005

Birdsey, J., Cornelius, M., Jamal, A., Park-Lee, E., Cooper, M. R., Wang, J., Sawdey, M. D.,

Cullen, K. A., & Neff, L. (2023). Tobacco product use among US middle and high school

students—National Youth Tobacco Survey, 2023. *MMWR. Morbidity and Mortality*

Weekly Report, 72(44), 1173–1182. https://doi.org/10.15585/mmwr.mm7244a1

Brown, P. L., & Jenkins, H. M. (1968). Auto-shaping of the pigeon's key-peck. *Journal of the*

Experimental Analysis of Behavior, 11(1), 1–8. https://doi.org/10.1901/jeab.1968.11-1

Buscher, N., Ojeda, A., Francoeur, M., Hulyalkar, S., Claros, C., Tang, T., Terry, A., Gupta, A.,

Fakhraei, L., & Ramanathan, D. S. (2020). Open-source raspberry Pi-based operant box

for translational behavioral testing in rodents. *Journal of Neuroscience Methods*, 342,

108761. https://doi.org/10.1016/j.jneumeth.2020.108761

Buynitsky, T., & Mostofsky, D. I. (2009). Restraint stress in biobehavioral research: Recent

developments. *Neuroscience & Biobehavioral Reviews, 33*(7), 1089–98.

https://doi.org/10.1016/j.neubiorev.2009.05.004

Castro, E. M., Lotfipour, S., & Leslie, F. M. (2023). Nicotine on the developing brain.

Pharmacological Research, 190, 106716. https://doi.org/10.1016/j.phrs.2023.106716

Centers for Disease Control and Prevention. (2024). *Health effects of vaping.*

https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html

Chaudhri, N., Caggiula, A. R., Donny, E. C., Booth, S., Gharib, M., Craven, L.,Palmatier, M. I.,

Lie, X., & Sved, A. F. (2007). Self-administered and noncontingent nicotine enhance

reinforced operant responding in rats: Impact of nicotine dose and reinforcement

schedule. *Psychopharmacology, 190*, 353-362.

https://doi.org/10.1007/s00213-006-0454-8

Chellian, R., Behnood-Rod, A., & Bruijnzeel, A. W. (2023). Development of dependence in

smokers and rodents with voluntary nicotine intake: Similarities and differences. *Nicotine

& Tobacco Research, 25*(7), 1229–1240. https://doi.org/10.1093/ntr/ntac280

Chellian, R., Behnood-Rod, A., & Bruijnzeel, A. W. (2024). Sex differences in nicotine intake

and relapse behavior in nicotine-dependent adult Wistar rats. *Frontiers in Pharmacology*,

15, 1415219. https://doi.org/10.3389/fphar.2024.1415219

Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.)*.* Routledge,

https://doi.org/10.4324/9780203771587

Cohen, J., & Cohen, P. (1983). *Applied multiple regression/correlation analysis for the

behavioral sciences (2nd ed.).* Hillsdale, NJ: Lawrence Erlbaum Associates.

Conover, W. J., & Iman, R. L. (1981). Rank transformations as a bridge between parametric and

nonparametric statistics. *The American Statistician, 35*(3), 124–129.

https://doi.org/10.1080/00031305.1981.10479327

Cooper, S. Y., Olszewski, N. A., Tetteh-Quarshie, S., Hill, S. P., Ghodsi, S., González-Castro, A., Willis, C. V., & Henderson, B. J. (2024). The impact of high or low doses of nicotine in a mouse model of vapor self-administration. *Nicotine & Tobacco Research, 26*(3), 316–323. https://doi.org/10.1093/ntr/ntad136

Cooper, S. Y., Willis, C. V., Richardson, M. R., Hill, S. P., Wright, S. K., Elmore, M. B., Mitchell, Z. B., González Castro, A. K., & Henderson, B. J. (2023). Chemical flavorants in vaping products alter neurobiology in a sex-dependent manner to promote vaping-related behaviors. *Journal of Neuroscience, 43*(8), 1360–1374. https://doi.org/10.1523/JNEUROSCI.0755-22.2022

Cornelius, M. E., Loretan, C. G., Wang, T. W., Jamal, A., & Homa, D. M. (2022). Tobacco product use among adults—United States, 2020. *MMWR. Morbidity and Mortality Weekly Report, 71.* http://dx.doi.org/10.15585/mmwr.mm7111a1

Cullen, K. A., Ambrose, B. K., Gentzke, A. S., Apelberg, B. J., Jamal, A., & King, B. A. (2018). Notes from the field: Use of electronic cigarettes and any tobacco product among middle and high school students - United States, 2011–2018. *Morbidity and Mortality Weekly Report, 67*(45), 1276–1277. http://dx.doi.org/10.15585/mmwr.mm6745a5

Cullen K. A., Gentzke, A. S, Sawdey M. D., Chang, J. T., Anic, G. M., Wang, T. W., Creamer, M. R., Jamal, J., Ambrose, B. K., & King, B. A. (2019). E-cigarette use among youth in the United States. *Journal of the American Medical Association, 322*(21), 2095–2103. https://doi.org/10.1001/jama.2019.18387

DeVito, E. E., & Krishnan-Sarin, S. (2018). E-cigarettes: Impact of e-liquid components and device characteristics on nicotine exposure. *Current Neuropharmacology, 16*(4),

438–459. https://doi.org/10.2174/1570159X15666171016164430

Donny, E. C., Caggiula, A. R., Mielke, M. M., Jacobs, K. S., Rose, C., & Sved, A. F. (1998). Acquisition of nicotine self-administration in rats: The effects of dose, feeding schedule, and drug contingency. *Psychopharmacology, 136*, 83-90. https://doi.org/10.1007/s002130050542

Duke, D., Wohlgemuth, E., Adams, K. R., Armstrong-Ingram, A., Rice, S. K., & Young, D. C. (2022). Earliest evidence for human use of tobacco in the Pleistocene Americas. *Nature Human Behaviour, 6(2),* 183–192. https://doi.org/10.1038/s41562-021-01202-9

England, L. J., Bunnell, R. E., Pechacek, T. F., Tong, V. T., & McAfee, T. A. (2015). Nicotine and the developing human: A neglected element in the electronic cigarette debate. *American Journal of Preventive Medicine*, *49*(2), 286-293. https://doi.org/10.1016/j.amepre.2015.01.015

Escobar, R., Gutiérrez, B., & Benavides, R. (2022). 3D-printed operant chambers for rats: Design, assembly, and innovations. *Behavioural Processes*, *199*, 104647. https://doi.org/10.1016/j.beproc.2022.104647

Escobar, R., & Pérez-Herrera, C. A. (2015). Low-cost USB interface for operant research using Arduino and Visual Basic. *Journal of the Experimental Analysis of Behavior, 103*(2), 427-435. https://doi.org/10.1002/jeab.135

Ferster, C. B., & Skinner, B. F. (1957). Variable ratio. In C. B. Ferster & B. F. Skinner, *Schedules of reinforcemen*t (pp. 396–419). Appleton-Century-Crofts. https://doi.org/10.1037/10627-007

Fleshler, M., & Hoffman, H. S. (1962). A progression for generating variable-interval schedules. *Journal of the Experimental Analysis of Behavior, 5*(4), 529–530.

https://doi.org/10.1901/jeab.1962.5-529

Frie, J. A., McCunn, P., Eed, A., Hassan, A., Luciani, K. R., Chen, C., Tyndale, R. F., & Khokhar, J. Y. (2023). Factors influencing JUUL e-cigarette nicotine vapour-induced reward, withdrawal, pharmacokinetics and brain connectivity in rats: Sex matters. *Neuropsychopharmacology, 49*(5), 782–795. https://doi.org/10.1038/s41386-023-01773-3

Friedman, M. (1937). The use of ranks to avoid the assumption of normality implicit in the analysis of variance. *Journal of the American Statistical Association*, *32*(200), 675–701. https://doi.org/10.2307/2279372

Gurley, K. (2019). Two open source designs for a low-cost operant chamber using Raspberry Pi. *Journal of the Experimental Analysis of Behavior, 111*(3), 508–518. https://doi.org/10.1002/jeab.520

Hair, E. C., Barton, A. A., Perks, S. N., Kreslake, J., Xiao, H., Pitzer, L., Leventhal, A. M., & Vallone, D. M. (2021). Association between e-cigarette use and future combustible cigarette use: Evidence from a prospective cohort of youth and young adults, 2017–2019. *Addictive Behaviors, 112,* Article 106593. https://doi.org/10.1016/j.addbeh.2020.106593

Henderson, B. J., Young, L. E., Olszewski, N. A., Tetteh-Quarshie, S., Maddox, S. K., Simpkins, M. A., Dudich, M. C., McGlauglin, M. S., Weinsweig, Z. C., & Cooper, S. Y. (2024). Age-dependent effects of vaping on the prefrontal cortex, ventral tegmental area, and nucleus accumbens. *Communications Biology, 7*(1), 1553. https://doi.org/10.1038/s42003-024-07272-5

Herman, M., & Tarran, R. (2020). E‑cigarettes, nicotine, the lung and the brain: Multi‑level cascading pathophysiology. *The Journal of Physiology, 598*(22), 5063-5071. https://doi.org/10.1113/JP278388

Jackson, A., Grobman, B., & Krishnan-Sarin, S. (2020). Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies. *Neuropharmacology, 176*, 108218. https://doi.org/10.1016/j.neuropharm.2020.108218

Kelsh, S., Ottney, A., Young, M., Kelly, M., Larson, R., & Sohn, M. (2023). Young adults' electronic cigarette use and perceptions of risk. *Tobacco Use Insights, 16*. https://doi.org/10.1177/1179173X231161313

Koffarnus, M. N., & Winger, G. (2015). Individual differences in the reinforcing and punishing effects of nicotine in rhesus monkeys. *Psychopharmacology, 232*, 2393–2403. https://doi.org/10.1007/s00213-015-3871-8

Kogel, U., Wong, E. T., Szostak, J., Tan, W. T., Lucci, F., Leroy, P., Titz, B., Xiang, Y., Low, T., Wong, S. K., Guedj, E., Ivanov, N. V., Schlage, W. K., Peitsch, M. C., Kuczaj, A., Vanscheeuwijck, P., & Hoeng, J. (2021). Impact of whole‑body versus nose‑only inhalation exposure systems on systemic, respiratory, and cardiovascular endpoints in a 2‑month cigarette smoke exposure study in the ApoE−/− mouse model. *Journal of Applied Toxicology, 41*(10), 1598-1619. https://doi.org/10.1002/jat.4149

Kurien, B. T., Everds, N. E., & Scofield, R. H. (2004). Experimental animal urine collection: A review. *Laboratory Animals, 38(4),* 333–361. https://doi.org/10.1258/0023677041958945

Kyonka, E. G. E., Mitchell, S. H., & Bizo, L. A. (2019). Beyond inference by eye: Statistical and graphing practices in *JEAB*, 1992-2017. *Journal of the Experimental Analysis of Behavior, 111*(2), 155–165. https://doi.org/10.1002/jeab.509

Lakens, D. (2013). Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for *t*-tests and ANOVAs. *Frontiers in Psychology, 4*, 863. https://doi.org/10.3389/fpsyg.2013.00863

Lallai, V., Chen, Y. C., Roybal, M. M., Kotha, E. R., Fowler, J. P., Staben, A., Cortez, A., & Fowler, C. D. (2021). Nicotine e-cigarette vapor inhalation and self-administration in a rodent model: Sex- and nicotine delivery-specific effects on metabolism and behavior. *Addiction Biology, 26*(6), e13024. https://doi.org/10.1111/adb.13024

Lattal, K. A. (1975). Reinforcement contingencies as discriminative stimuli. *Journal of the Experimental Analysis of Behavior, 23*(2), 241-246. https://doi.org/10.1901/jeab.1975.23-241

Lattal, K. A. (1995). Contingency and behavior analysis. *The Behavior Analyst, 18*, 209-224. https://doi.org/10.1007/BF03392709

Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Prabhat, J., & Hall, W. D. (2022). Tobacco and nicotine use. *Nature Reviews Disease Primers, 8*(1), 19. https://doi.org/10.1038/s41572-022-00346-w

Leslie, F. M. (2020). Unique, long-term effects of nicotine on adolescent brain. *Pharmacology, Biochemistry, and Behavior, 197*, 173010. https://doi.org/10.1016/j.pbb.2020.173010

Leventhal, A., Cho, J., Barrington-Trimis, J., Pang, R., Schiff, S., & Kirkpatrick, M. (2020). Sensory attributes of e-cigarette flavours and nicotine as mediators of interproduct differences in appeal among young adults. *Tobacco Control, 29*(6), 679–686. https://doi.org/10.1136/tobaccocontrol-2019-055172

Leventhal, A. M., Goldenson, N. I., Cho, J., Kirkpatrick, M. G., McConnell, R. S., Stone, M. D., Pang, R. D., Audrain-McGovern, J., & Barrington-Trimis, J. L. (2019). Flavored e-cigarette use and progression of vaping in adolescents. *Pediatrics, 144*(5), e20190789. https://doi.org/10.1542/peds.2019-0789

Leventhal, A. M., Madden, D. R., Peraza, N., Schiff, S. J., Lebovitz, L., Whitted, L.,

Barrington-Trimis, J., Mason, T. B., Anderson, M. K., & Tackett, A. P. (2021). Effect of

    exposure to e-cigarettes with salt vs free-base nicotine on the appeal and sensory

    experience of vaping: A randomized clinical trial. *JAMA Network Open, 4*(1), e2032757.

    https://doi.org/10.1001/jamanetworkopen.2020.32757

Li, L., Lin, Y., Xia, T., & Zhu, Y. (2020). Effects of electronic cigarettes on indoor air quality and

    health. *Annual Review of Public Health, 41*, 363-380.

    https://doi.org/10.1146/annurev-publhealth-040119-094043

Lucci, F., Tan, W. T., Krishnan, S., Hoeng, J., Vanscheeuwijck, P., Jaeger, R., & Kuczaj, A.,

    (2020). Experimental and computational investigation of a nose-only exposure chamber.

    Aerosol Science and Technology, 54(3), 277-290.

    https://doi.org/10.1080/02786826.2019.1687843

Malin, D. H., Lake, J. R., Newlin-Maultsby, P., Roberts, L. K., Lanier, J. G., Carter, V. A.,

    Cunningham, J. S., & Wilson, O. B. (1992). Rodent model of nicotine abstinence

    syndrome. *Pharmacology, Biochemistry, and Behavior*, *43*(3), 779–784.

    https://doi.org/10.1016/0091-3057(92)90408-8

Malin, D. H., Lake, J. R., Payne, M. C., Short, P. E., Carter, V. A., Cunningham, J. S., & Wilson,

    O. B. (1996). Nicotine alleviation of nicotine abstinence syndrome is

    naloxone-reversible. *Pharmacology, Biochemistry, and Behavior, 53*(1), 81–85.

    https://doi.org/10.1016/0091-3057(95)00202-2

Malin, D. H., Lake, J. R., Shenoi, M., Upchurch, T. P., Johnson, S. C., Schweinle, W. E., &

    Cadle, C. D. (1998). The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA)

    attenuates nicotine abstinence syndrome in the rat. *Psychopharmacology, 140*, 371–377.

    https://doi.org/10.1007/s002130050778

Marusich, J. A., & Palmatier, M. I. (2023). Development of a nicotine aerosol self-administration model in rats and the effects of e-liquid flavors. *Behavioural Pharmacology, 34*(2-3), 141-153. https://doi.org/10.1097/FBP.0000000000000717

Morris, A. M., Leonard, S. S., Fowles, J. R., Boots, T. E., Mnatsakanova, A., & Attfield, K. R. (2021). Effects of e-cigarette flavoring chemicals on human macrophages and bronchial epithelial cells. *International Journal of Environmental Research and Public Health, 18*(21), 11107. https://doi.org/10.3390/ijerph182111107

Moussawi, K., Ortiz, M. M., Gantz, S. C., Tunstall, B. J., Marchette, R. C. N., Bonci, A., Koob, G. F., & Vendruscolo, L. F. (2020). Fentanyl vapor self-administration model in mice to study opioid addiction. *Science Advances, 6*(32), eabc0413. https://doi.org/10.1126/sciadv.abc0413

National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs). (N.D.). *The 3Rs.* Retrieved December 17, 2024 from https://www.nc3rs.org.uk/who-we-are/3rs

Odum, A. L., Callister, K. T., Willis-Moore, M. E., Da Silva, D. S., Legaspi, D. N., Scribner, L. N., & Hannah, J. N. (2024). Zoographics in the *Journal of the Experimental Analysis of Behavior*: Increasing inclusion of female animals. *Journal of the Experimental Analysis of Behavior*, *122*(3), 392–407. https://doi.org/10.1002/jeab.4220

Park, H., O'Sullivan, M., Vallarino, J., Shumyatcher, M., Himes, B., Park, J., Christiani, D. C., Allen, J., & Lu, Q. (2019). Transcriptomic response of primary human airway epithelial cells to flavoring chemicals in electronic cigarettes. *Nature, 9*(1400), 1–11. https://doi.org/10.1038/s41598-018-37913-9

Park, M. B., & Choi, J. K. (2019). Differences between the effects of conventional cigarettes,

e-cigarettes and dual product use on urine cotinine levels. *Tobacco Induced Diseases, 17*, 12. https://doi.org/10.18332/tid/100527

Park-Lee, E., Ren, C., Sawdey, M. D., Gentzke, A. S., Cornelius, M., Jamal, A., & Cullen, K. A. (2021). Notes from the field: E-cigarette use among middle and high school students - National Youth Tobacco Survey, United States, 2021. *MMWR. Morbidity and Mortality Weekly Report, 70*(39), 1387–1389. https://doi.org/10.15585/mmwr.mm7039a4

Perone, M. (1991). Experimental design in the analysis of free-operant behavior. In I. H. Iversen & K. A. Lattal (Eds.), *Experimental analysis of behavior, Parts 1 & 2* (pp. 135–171). Elsevier Science.

Pittenger, S. T., Swalve, N., Chou, S., Smith, M. D., Hoonakker, A. J., Pudiak, C. M., Fleckenstein, A. E., Hanson, G. R., & Bevins, R. A. (2016). Sex differences in neurotensin and substance P following nicotine self-administration in rats. *Synapse, 70*(8), 336–346. https://doi.org/10.1002/syn.21907

Pogun, S., Yararbas, G., Nesil, T., & Kanit, L. (2017). Sex differences in nicotine preference. *Journal of Neuroscience Research, 95*(1-2), 148–162. https://doi.org/10.1002/jnr.23858

Qazi, S. U., Ansari, M. H., Ghazanfar, S., Ghazanfar, S. S., & Farooq, M. (2024). Comparison of acute effects of e-cigarettes with and without nicotine and tobacco cigarettes on hemodynamic and endothelial parameters: A systematic review and meta-analysis. *High Blood Pressure & Cardiovascular Prevention, 31*(3), 225-237. https://doi.org/10.1007/s40292-024-00643-3

Rapp, J. L., Alpert, N., Flores, R. M., & Taioli, E. (2020). Serum cotinine levels and nicotine addiction potential of e-cigarettes: An NHANES analysis. *Carcinogenesis, 41*(10), 1454–1459. https://doi.org/10.1093/carcin/bgaa015

Reitsma, M. B., Flor, L. S., Mullany, E. C., Gupta, V., Hay, S. I., & Gakidou, E. (2021). Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and initiation among young people in 204 countries and territories, 1990–2019. *The Lancet Public Health, 6*(7), 472-481. https://doi.org/10.1016/S2468-2667(21)00102

Rizzi, G., Lodge, M. E., Tan, K. R. (2016). Design and construction of a low-cost nose poke system for rodents. *MethodsX, 3*, 326-332. https://doi.org/10.1016/j.mex.2016.04.002

Rubery, H. (2022, October 20). *Why nicotine salts & what devices work best with them*. MYVAPERY .https://www.myvapery.com/blog/post/why-nicotine-salts-and-what-devices-work-best-with-them

Scherer, G., Mütze, J., Pluym, N., & Scherer, M. (2022). Assessment of nicotine delivery and uptake in users of various tobacco/nicotine products. *Current Research in Toxicology, 3,* 100067. https://doi.org/10.1016/j.crtox.2022.100067

Schroeder, M. J., & Hoffman, A. C. (2014). Electronic cigarettes and nicotine clinical pharmacology. *Tobacco Control*, *23*, ii30–ii35. https://doi.org/10.1136/tobaccocontrol-2013-051469

Shapiro, S. S., & Wilk, M. B. (1965) An analysis of variance test for normality (complete samples). *Biometrika, 52*, 591-611. https://doi.org/10.1093/biomet/52.3-4.591

Shearston, J. A., Eazor, J., Lee, L., Vilcassim, M. J. R., Reed, T. A., Ort, D., Weitzman, M., & Gordon, T. (2023). Effects of electronic cigarettes and hookah (waterpipe) use on home air quality. *Tobacco Control, 32*(1), 36–41. https://doi.org/10.1136/tobaccocontrol-2020-056437

Shehata, S. A., Toraih, E. A., Ismail, E. A., Hagras, A. M., Elmorsy, E., & Fawzy, M. S. (2023).

Vaping, environmental toxicants exposure, and lung cancer risk. *Cancers*, *15*(18), 4525.

https://doi.org/10.3390/cancers15184525

Shelton, K. L., & Nicholson, K. L. (2022). Reinforcing effects of fentanyl and sufentanil aerosol

puffs in rats. *Psychopharmacology, 239(8),* 2491–2502.

https://doi.org/10.1007/s00213-022-06129-1

Shoaib, M., & Stolerman, I. P. (1995). Conditioned taste aversions in rats after intracerebral

administration of nicotine. *Behavioural Pharmacology, 6*(4), 375–385.

https://doi.org/10.1097/00008877-199506000-00008

Shoaib, M., & Stolerman, I. P. (1999). Plasma nicotine and cotinine levels following intravenous

nicotine self administration in rats. *Psychopharmacology, 143*, 318-321.

https://doi.org/10.1007/s002130050

Smith, L. C., Kallupi, M., Tieu, L., Shankar, K., Jaquish, A., Barr, J., Su, Y., Velarde, N.,

Sedighim, S., Carrette, L. L. G., Klodnicki, M., Sun, X., de Guglielmo, G., & George, O.

(2020). Validation of a nicotine aerosol self-administration model in rats with relevance

to electronic cigarette use. *Neuropsychopharmacology, 45*, 1909–1919.

https://doi.org/10.1038/s41386-020-0734-8

St. Helen, G., Shahid, M., Chu, S., & Benowitz, N. L. (2018). Impact of e-liquid flavors on

e-cigarette vaping behavior. *Drug and Alcohol Dependence, 189*, 42–48.

https://doi.org/10.1016/j.drugalcdep.2018.04.032

Suarez, M., Charntikov, S., Huynh, Y. W., Barrett, S. T., Bevins, R. A., & Wakabayashi, K. T.

(2024). A robust and simple catheter connector assembly for long-term

self-administration experiments. *MethodsX, 12,* 102675.

https://doi.org/10.1016/j.mex.2024.102675

Sullivan, L. M., Weinberg, J., & Keaney Jr, J. F. (2016). Common statistical pitfalls in basic science research. *Journal of the American Heart Association, 5*(10), e004142. https://doi.org/10.1161/JAHA.116.004142

Tashakkori, N. A., Park-Lee, E., Roh, E. J., & Christensen, C. H. (2023). Multiple tobacco product use among youth e-cigarette users: National youth tobacco survey, 2020. *Journal of Adolescent Health*, *73*(4), 769-775. https://doi.org/10.1016/j.jadohealth.2023.05.025

U.S. Department of Health and Human Services. (2014). *The health consequences of smoking - 50 years of progress: A report of the surgeon general.* Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. https://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf

U.S. Department of Health and Human Services. (2016). *E-Cigarette use among youth and young adults: A report of the surgeon general - Executive summary.* Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. https://www.cdc.gov/tobacco/data_statistics/sgr/e-cigarettes/pdfs/2016_sgr_entire_report _508.pdf

United States Environmental Protection Agency. (2024, December 17). *National Ambient Air Quality Standards (NAAQS) for PM.* https://www.epa.gov/pm-pollution/national-ambient-air-quality-standards-naaqs-pm#rule -summary

Van Herck, H., Baumans, V., Brandt, C. J. W. M., Boere, H. A. G., Hesp, A. P. M., Van Lith, H. A., Schurink, M., & Beynen, A. C. (2001). Blood sampling from the retro-orbital plexus,

the saphenous vein and the tail vein in rats: comparative effects on selected behavioural and blood variables. *Laboratory animals, 35*(2), 131-139. https://doi.org/10.1258/002367701191149

Vu, G. T., Stjepanović, D., Sun, T., Leung, J., Chung, J., Connor, J., Thai, P. K., Gartner, C. E., Tran, B. X., Hall, W. D., & Chan, G. (2024). Predicting the long-term effects of electronic cigarette use on population health: A systematic review of modelling studies. *Tobacco Control, 33(6),* 790–797. https://doi.org/10.1136/tc-2022-057748

Wang, T. W. (2020). E-cigarette use among middle and high school students—United States, 2020. *MMWR. Morbidity and Mortality Weekly Report, 69.* http://dx.doi.org/10.15585/mmwr.mm6937e1

Wilkinson, J. L., & Bevins, R. A. (2008). Intravenous nicotine conditions a place preference in rats using an unbiased design. *Pharmacology Biochemistry and Behavior, 88*(3), 256-264. https://doi.org/10.1016/j.pbb.2007.08.009

Yuan, M., Cross, S. J., Loughlin, S. E., & Leslie, F. M. (2015). Nicotine and the adolescent brain. *Journal of Physiology, 593*(16), 3397–3412. https://doi.org/10.1113/JP270492

Zare, S., Nemati, M., & Zheng, Y. (2018). A systematic review of consumer preference for e-cigarette attributes: Flavor, nicotine strength, and type. *PloS one, 13*(3), e0194145. https://doi.org/10.1371/journal.pone.0194145

Zhang, X., Sun, Y., Cheung, Y. T. D., Wang, M. P., Wu, Y. S., Chak, K. Y., Chen, J., Leung, L. T., Lam, T. H., & Ho, S. Y. (2024). Cigarettes, heated tobacco products and dual use: Exhaled carbon monoxide, saliva cotinine and total tobacco consumed by Hong Kong tobacco users. *Tobacco Control, 33(4),* 457–463. https://doi.org/10.1136/tc-2022-057598

Table 1

RENDS Components by Description and Cost for Four Chambers

Quantity	Component Description	Unit Amount	Total Price (USD)
1	Air compressor		349.00
4	Air regulator		67.96
4	Ball pump needle	2	3.84
4	E-cigarette (Drag X)		179.96
4	E-cigarette holder PLA print		13.44
8	Photo beam		23.60
8	Resin printed port		40.00
8	Silicon tubing adapter	5	29.76
4	Solenoid		154.00
8	Stainless steel adjustable clamp	10	2.48
1	Tailonz pneumatic tubing	50 ft	18.99
1	Vacuum cleaner		109.99
4	Vacuum generator		211.20
1	Vacuum tubing	30 ft	52.87
1	Vacuum tubing splitter		4.42
			1,261.51

Note. This table includes all components for four RENDS chambers. One air compressor and one vacuum cleaner can support up to six chambers, which would reduce the per chamber cost.

Figure 1

The RENDS Diagram

Note. The retrofit of the RENDS in a standard operant chamber. Active and inactive ports have photobeams that shine through the opening of the sides of each port. Nicotine aerosol is pulled into the active port through an air compressor and vacuum generator, and excess aerosol is exhausted through a vacuum. Created with BioRender.com.

Figure 2

The RENDS E-Cigarette Holder

Note. A solid (left) and wireframe (right) isometric view of the RENDS e-cigarette holder. A

solenoid is placed in the upper left cylindrical compartment and is held in place by a removable

PLA stopper. When activated, the solenoid shaft extends and presses the 'on' button of the

e-cigarette, which is situated inside the main compartment on the right. Cut out areas in the main

compartment help prevent overheating of the e-cigarette.

Figure 3

RENDS Nose Port

Note. A solid (left) and wireframe (right) isometric view of the front of the nose port, with an

opening diameter of approximately 2 cm (0.78 in.) and a depth of approximately 2 cm (0.78 in.).

Different regions are denoted as follows: two photo beam path cutouts (blue, lateral interior),

liquid reservoir (red, bottom interior), nicotine aerosol inlet tube (purple, top interior), and four

vacuum outlet tubes (orange, exterior)

Figure 4

Measurements of Chamber Air Quality Across Three Conditions

Note. Mean PM2.5 levels across three conditions: room air, e-cigarette puffs with vacuum system on, and e-cigarette puffs with vacuum system off. Individual symbols show data from different determinations and bars show the mean of a condition. Green symbols and bars indicate values which fall below the 9 $\mu g/m^3$ cut off for 'good' PM2.5 levels; maroon symbols and bar indicate values which exceed the 225.5 $\mu g/m^3$ designation of 'hazardous' PM2.5 levels (USEPA, 2024, Table 2). Green left and center symbols and bars show values from the room air and vacuum system on conditions, and the maroon right symbols and and bar show data from the vacuum system off condition. Note the break in the *y*-axis to accommodate the wide range of values.

Figure 5

Cumulative Records for Baseline (VR2, Left Column), Extinction, and Return to Baseline (VR2, Right Column) Conditions for Male and Female Rats

Note. Cumulative records of responding from the last session of baseline (VR2, left column), extinction (EXT), and return to baseline (VR2, right column). Top rows show data from male nicotine subjects (purple lines and symbols); bottom rows show data from female nicotine subjects (orange lines and symbols). Solid lines show active nose pokes, and broken lines show inactive nose pokes. Tick marks indicate nicotine aerosol delivery (reinforcers).

Figure 6

Total Nose Pokes Across the Last Six Sessions for Each Rat for Each Condition

Note. Data show total number of nose pokes for the four nicotine subjects for the last six sessions of each respective condition: baseline (VR2, left), extinction (EXT), and return to baseline (VR2, right). Top panels depict data from male subjects (purple) and bottom panels depict data from female subjects (orange). Darker shades with solid lines indicate active port nose pokes (upright triangles and circles) and lighter shades with broken lines indicate inactive port nose pokes (inverted triangles and squares).

Figure 7

Blood Levels of Cotinine as a Function of E-Cigarette Puffs Earned

Note. Cotinine (nicotine metabolite) levels for rats that self-administered nicotine aerosol as a function of the number of puffs earned. Symbols in purple and orange represent data from male and female subjects, respectively. Lighter points by the origin are from extinction conditions when nicotine aerosol was not available.

Figure 8

Overall Occurrence of Spontaneous Somatic Withdrawal Symptoms

Note. Mean total withdrawal score for male and female rats that self-administered nicotine aerosol (N) and control (C) rats. Purple and orange bars and symbols represent data from male and female rats, respectively. Darker bars denote data from nicotine subjects and lighter bars denote data from control rats that did not self-administer nicotine aerosol. Symbols denote the range.